nach oben

Cancer and Metastasis Reviews

Erschienen in:

07.06.2023

Epigenetic markers and therapeutic targets for metastasis

verfasst von: Carolyn J. Kravitz, Qin Yan, Don X. Nguyen

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

The last few years have seen an increasing number of discoveries which collectively demonstrate that histone and DNA modifying enzyme modulate different stages of metastasis. Moreover, epigenomic alterations can now be measured at multiple scales of analysis and are detectable in human tumors or liquid biopsies. Malignant cell clones with a proclivity for relapse in certain organs may arise in the primary tumor as a consequence of epigenomic alterations which cause a loss in lineage integrity. These alterations may occur due to genetic aberrations acquired during tumor progression or concomitant to therapeutic response. Moreover, evolution of the stroma can also alter the epigenome of cancer cells. In this review, we highlight current knowledge with a particular emphasis on leveraging chromatin and DNA modifying mechanisms as biomarkers of disseminated disease and as therapeutic targets to treat metastatic cancers.

Massague, J., & Obenauf, A. C. (2016). Metastatic colonization by circulating tumour cells. Nature, 529(7586), 298–306. https://doi.org/10.1038/nature17038CrossRefPubMedPubMedCentral

Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017). Emerging biological principles of metastasis. Cell, 168(4), 670–691. https://doi.org/10.1016/j.cell.2016.11.037CrossRefPubMedPubMedCentral

Celia-Terrassa, T., & Kang, Y. (2018). Metastatic niche functions and therapeutic opportunities. Nature Cell Biology, 20(8), 868–877. https://doi.org/10.1038/s41556-018-0145-9CrossRefPubMed

Quail, D. F., & Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. Cancer Cell, 31(3), 326–341. https://doi.org/10.1016/j.ccell.2017.02.009CrossRefPubMedPubMedCentral

Nguyen, B., Fong, C., Luthra, A., Smith, S. A., DiNatale, R. G., Nandakumar, S., et al. (2022). Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 185(3), 563–575.e511. https://doi.org/10.1016/j.cell.2022.01.003CrossRefPubMedPubMedCentral

Aftimos, P., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C., Gal-Yam, E. N., et al. (2021). Genomic and Transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 11(11), 2796–2811. https://doi.org/10.1158/2159-8290.CD-20-1647CrossRefPubMedPubMedCentral

Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., et al. (2019). Pan-cancer whole-genome analyses of metastatic solid tumours. Nature, 575(7781), 210–216. https://doi.org/10.1038/s41586-019-1689-yCrossRefPubMedPubMedCentral

Patel, S. A., & Vanharanta, S. (2017). Epigenetic determinants of metastasis. Molecular Oncology, 11(1), 79–96. https://doi.org/10.1016/j.molonc.2016.09.008CrossRefPubMedPubMedCentral

Marine, J. C., Dawson, S. J., & Dawson, M. A. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nature Reviews Cancer, 20(12), 743–756. https://doi.org/10.1038/s41568-020-00302-4CrossRefPubMed

10.

Chen, J. F., & Yan, Q. (2021). The roles of epigenetics in cancer progression and metastasis. The Biochemical Journal, 478(17), 3373–3393. https://doi.org/10.1042/bcj20210084CrossRefPubMed

11.

Feinberg, A. P., & Tycko, B. (2004). The history of cancer epigenetics. Nature Reviews. Cancer, 4(2), 143–153. https://doi.org/10.1038/nrc1279CrossRefPubMed

12.

Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013). Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature Reviews Genetics, 14(11), 765–780. https://doi.org/10.1038/nrg3554CrossRefPubMed

13.

Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016). Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nature Reviews Genetics, 17(5), 284–299. https://doi.org/10.1038/nrg.2016.13CrossRefPubMedPubMedCentral

14.

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019). The roles of DNA, RNA and histone methylation in ageing and cancer. Nature Reviews Molecular Cell Biology, 20(10), 573–589. https://doi.org/10.1038/s41580-019-0143-1CrossRefPubMed

15.

Alix-Panabières, C., & Pantel, K. (2021). Liquid biopsy: From discovery to clinical application. Cancer Discovery, 11(4), 858–873. https://doi.org/10.1158/2159-8290.Cd-20-1311CrossRefPubMed

16.

Sadeh, R., Sharkia, I., Fialkoff, G., Rahat, A., Gutin, J., Chappleboim, A., et al. (2021). ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nature Biotechnology, 39(5), 586–598. https://doi.org/10.1038/s41587-020-00775-6CrossRefPubMedPubMedCentral

17.

Jamshidi, A., Liu, M. C., Klein, E. A., Venn, O., Hubbell, E., Beausang, J. F., et al. (2022). Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell, 40(12), 1537–1549.e1512. https://doi.org/10.1016/j.ccell.2022.10.022CrossRefPubMed

18.

Ring, A., Nguyen-Sträuli, B. D., Wicki, A., & Aceto, N. (2022). Biology, vulnerabilities and clinical applications of circulating tumour cells. Nature Reviews. Cancer, 1-17. https://doi.org/10.1038/s41568-022-00536-4

19.

Buscail, E., Chiche, L., Laurent, C., Vendrely, V., Denost, Q., Denis, J., et al. (2019). Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. Molecular Oncology, 13(9), 1811–1826. https://doi.org/10.1002/1878-0261.12534CrossRefPubMedPubMedCentral

20.

Costa, C., & Dávila-Ibáñez, A. B. (2020). Methodology for the isolation and analysis of CTCs. Advances in Experimental Medicine and Biology, 1220, 45–59. https://doi.org/10.1007/978-3-030-35805-1_4CrossRefPubMed

21.

Simpson, K. L., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., et al. (2020). A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nat Cancer, 1(4), 437–451. https://doi.org/10.1038/s43018-020-0046-2CrossRefPubMed

22.

Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., et al. (2021). The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discovery, 11(3), 678–695. https://doi.org/10.1158/2159-8290.Cd-19-1500CrossRefPubMed

23.

Zhang, L., Ridgway, L. D., Wetzel, M. D., Ngo, J., Yin, W., Kumar, D., et al. (2013). The identification and characterization of breast cancer CTCs competent for brain metastasis. Science Translational Medicine, 5(180), 180ra148. https://doi.org/10.1126/scitranslmed.3005109CrossRef

24.

Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 31(6), 539–544. https://doi.org/10.1038/nbt.2576CrossRefPubMed

25.

Padmanaban, V., Krol, I., Suhail, Y., Szczerba, B. M., Aceto, N., Bader, J. S., et al. (2019). E-cadherin is required for metastasis in multiple models of breast cancer. Nature, 573(7774), 439–444. https://doi.org/10.1038/s41586-019-1526-3CrossRefPubMedPubMedCentral

26.

Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., et al. (2020). Lymph protects metastasizing melanoma cells from ferroptosis. Nature, 585(7823), 113–118. https://doi.org/10.1038/s41586-020-2623-zCrossRefPubMedPubMedCentral

27.

Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., et al. (2015). Oxidative stress inhibits distant metastasis by human melanoma cells. Nature, 527(7577), 186–191. https://doi.org/10.1038/nature15726CrossRefPubMedPubMedCentral

28.

Sprouse, M. L., Welte, T., Boral, D., Liu, H. N., Yin, W., Vishnoi, M., et al. (2019). PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling. International Journal of Molecular Sciences, 20(8). https://doi.org/10.3390/ijms20081916

29.

Bowley, T. Y., Lagutina, I. V., Francis, C., Sivakumar, S., Selwyn, R. G., Taylor, E., et al. (2022). The RPL/RPS gene signature of melanoma CTCs associates with brain metastasis. Cancer Research Communications, 2(11), 1436–1448. https://doi.org/10.1158/2767-9764.crc-22-0337CrossRefPubMedPubMedCentral

30.

Ebright, R. Y., Lee, S., Wittner, B. S., Niederhoffer, K. L., Nicholson, B. T., Bardia, A., et al. (2020). Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science, 367(6485), 1468–1473. https://doi.org/10.1126/science.aay0939CrossRefPubMedPubMedCentral

31.

Cai, W. L., Chen, J. F., Chen, H., Wingrove, E., Kurley, S. J., Chan, L. H., et al. (2022). Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife, 11. https://doi.org/10.7554/eLife.78163

32.

Aho, E. R., Wang, J., Gogliotti, R. D., Howard, G. C., Phan, J., Acharya, P., et al. (2019). Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity. Cell Reports, 26(11), 2916–2928. e2913. https://doi.org/10.1016/j.celrep.2019.02.047CrossRefPubMed

33.

Guarnaccia, A. D., & Tansey, W. P. (2018). Moonlighting with WDR5: A cellular multitasker. Journal of Clinical Medicine, 7(2). https://doi.org/10.3390/jcm7020021

34.

Schuster, E., Taftaf, R., Reduzzi, C., Albert, M. K., Romero-Calvo, I., & Liu, H. (2021). Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer, 7(11), 1020–1032. https://doi.org/10.1016/j.trecan.2021.07.001CrossRefPubMedPubMedCentral

35.

Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122. https://doi.org/10.1016/j.cell.2014.07.013CrossRefPubMedPubMedCentral

36.

Liu, X., Taftaf, R., Kawaguchi, M., Chang, Y. F., Chen, W., Entenberg, D., et al. (2019). Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discovery, 9(1), 96–113. https://doi.org/10.1158/2159-8290.Cd-18-0065CrossRefPubMed

37.

Wei, R. R., Sun, D. N., Yang, H., Yan, J., Zhang, X., Zheng, X. L., et al. (2018). CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacologica Sinica, 39(8), 1326–1337. https://doi.org/10.1038/aps.2017.189CrossRefPubMedPubMedCentral

38.

Wrenn, E. D., Yamamoto, A., Moore, B. M., Huang, Y., McBirney, M., Thomas, A. J., et al. (2020). Regulation of collective metastasis by nanolumenal signaling. Cell, 183(2), 395–410.e319. https://doi.org/10.1016/j.cell.2020.08.045CrossRefPubMedPubMedCentral

39.

Gkountela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., et al. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell, 176(1-2), 98–112.e114. https://doi.org/10.1016/j.cell.2018.11.046CrossRefPubMedPubMedCentral

40.

Chang, P. H., Chen, M. C., Tsai, Y. P., Tan, G. Y. T., Hsu, P. H., Jeng, Y. M., et al. (2021). Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 118(3). https://doi.org/10.1073/pnas.2014408118

41.

Szczerba, B. M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., et al. (2019). Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 566(7745), 553–557. https://doi.org/10.1038/s41586-019-0915-yCrossRefPubMed

42.

Chimonidou, M., Strati, A., Malamos, N., Kouneli, S., Georgoulias, V., & Lianidou, E. (2017). Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. Oncotarget, 8(42), 72054–72068. https://doi.org/10.18632/oncotarget.18679CrossRefPubMedPubMedCentral

43.

Strati, A., Zavridou, M., Kallergi, G., Politaki, E., Kuske, A., Gorges, T. M., et al. (2021). A comprehensive molecular analysis of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer. Clinical Chemistry, 67(10), 1395–1405. https://doi.org/10.1093/clinchem/hvab099CrossRefPubMed

44.

Pixberg, C. F., Raba, K., Müller, F., Behrens, B., Honisch, E., Niederacher, D., et al. (2017). Analysis of DNA methylation in single circulating tumor cells. Oncogene, 36(23), 3223–3231. https://doi.org/10.1038/onc.2016.480CrossRefPubMed

45.

Cheng, H. H., Plets, M., Li, H., Higano, C. S., Tangen, C. M., Agarwal, N., et al. (2018). Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate, 78(2), 121–127. https://doi.org/10.1002/pros.23452CrossRefPubMed

46.

Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., et al. (2018). EMT subtype influences epithelial plasticity and mode of cell migration. Developmental Cell, 45(6), 681–695.e684. https://doi.org/10.1016/j.devcel.2018.05.027CrossRefPubMedPubMedCentral

47.

Cheung, K. J., Padmanaban, V., Silvestri, V., Schipper, K., Cohen, J. D., Fairchild, A. N., et al. (2016). Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proceedings of the National Academy of Sciences of the United States of America, 113(7), E854–E863. https://doi.org/10.1073/pnas.1508541113CrossRefPubMedPubMedCentral

48.

Lim, A. R., & Ghajar, C. M. (2022). Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse. Seminars in Cancer Biology, 78, 104–123. https://doi.org/10.1016/j.semcancer.2021.05.007CrossRefPubMed

49.

Sosa, M. S., Parikh, F., Maia, A. G., Estrada, Y., Bosch, A., Bragado, P., et al. (2015). NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nature Communications, 6, 6170. https://doi.org/10.1038/ncomms7170CrossRefPubMed

50.

Borgen, E., Rypdal, M. C., Sosa, M. S., Renolen, A., Schlichting, E., Lønning, P. E., et al. (2018). NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Research, 20(1), 120. https://doi.org/10.1186/s13058-018-1049-0CrossRefPubMedPubMedCentral

51.

Gawrzak, S., Rinaldi, L., Gregorio, S., Arenas, E. J., Salvador, F., Urosevic, J., et al. (2018). MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+) breast cancer. Nature Cell Biology, 20(2), 211–221. https://doi.org/10.1038/s41556-017-0021-zCrossRefPubMed

52.

Clements, M. E., Holtslander, L., Edwards, C., Todd, V., Dooyema, S. D. R., Bullock, K., et al. (2021). HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. Oncogene, 40(34), 5314–5326. https://doi.org/10.1038/s41388-021-01931-1CrossRefPubMedPubMedCentral

53.

Johnson, R. W., Finger, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., et al. (2016). Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nature Cell Biology, 18(10), 1078–1089. https://doi.org/10.1038/ncb3408CrossRefPubMedPubMedCentral

54.

Sun, D., Singh, D. K., Carcamo, S., Filipescu, D., Khalil, B., Huang, X., et al. (2022). MacroH2A impedes metastatic growth by enforcing a discrete dormancy program in disseminated cancer cells. Science Advances, 8(48), eabo0876. https://doi.org/10.1126/sciadv.abo0876CrossRefPubMed

55.

Shen, M., & Kang, Y. (2020). Stresses in the metastatic cascade: Molecular mechanisms and therapeutic opportunities. Genes & Development, 34(23-24), 1577–1598. https://doi.org/10.1101/gad.343251.120CrossRef

56.

Nishida, J., Momoi, Y., Miyakuni, K., Tamura, Y., Takahashi, K., Koinuma, D., et al. (2020). Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nature Cell Biology, 22(4), 465–475. https://doi.org/10.1038/s41556-020-0491-2CrossRefPubMed

57.

Zhang, M., Liu, Z. Z., Aoshima, K., Cai, W. L., Sun, H., Xu, T., et al. (2022). CECR2 drives breast cancer metastasis by promoting NF-kappaB signaling and macrophage-mediated immune suppression. Science Translational Medicine, 14(630), eabf5473. https://doi.org/10.1126/scitranslmed.abf5473CrossRefPubMedPubMedCentral

58.

Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., et al. (2018). Immunological differences between primary and metastatic breast cancer. Annals of Oncology, 29(11), 2232–2239. https://doi.org/10.1093/annonc/mdy399CrossRefPubMed

59.

Cao, J., & Yan, Q. (2020). Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer, 6(7), 580–592. https://doi.org/10.1016/j.trecan.2020.02.003CrossRefPubMedPubMedCentral

60.

Micevic, G., Bosenberg, M. W., & Yan, Q. (2022). The crossroads of cancer epigenetics and immune checkpoint therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-22-0784

61.

Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119(7), 941–953.CrossRefPubMed

62.

Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., et al. (2018). LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell, 174(3), 549–563. e519. https://doi.org/10.1016/j.cell.2018.05.052CrossRefPubMedPubMedCentral

63.

Zhang, S. M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., et al. (2021). KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature, 598(7882), 682–687. https://doi.org/10.1038/s41586-021-03994-2CrossRefPubMedPubMedCentral

64.

Hu, H., Khodadadi-Jamayran, A., Dolgalev, I., Cho, H., Badri, S., Chiriboga, L. A., et al. (2021). Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity. Cancer Immunology Research, 9(11), 1298-1315. https://doi.org/10.1158/2326-6066.CIR-21-0543.

65.

Lin, J., Guo, D., Liu, H., Zhou, W., Wang, C., Muller, I., et al. (2021). The SETDB1-TRIM28 complex suppresses antitumor immunity. Cancer Immunology Research, 9(12), 1413–1424. https://doi.org/10.1158/2326-6066.CIR-21-0754CrossRefPubMedPubMedCentral

66.

Guo, E., Xiao, R., Wu, Y., Lu, F., Liu, C., Yang, B., et al. (2022). WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. The Journal of Experimental Medicine, 219(1). https://doi.org/10.1084/jem.20210789

67.

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., et al. (2021). Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature, 595(7866), 309–314. https://doi.org/10.1038/s41586-021-03520-4CrossRefPubMedPubMedCentral

68.

Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I. K., et al. (2021). Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discovery, 11(3), 736–753. https://doi.org/10.1158/2159-8290.CD-20-0519CrossRefPubMed

69.

Chan, I. S., Knutsdottir, H., Ramakrishnan, G., Padmanaban, V., Warrier, M., Ramirez, J. C., et al. (2020). Cancer cells educate natural killer cells to a metastasis-promoting cell state. The Journal of Cell Biology, 219(9). https://doi.org/10.1083/jcb.202001134

70.

Garcia-Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B. J., Garrido-Castro, A. C., Pascual, T., et al. (2023). Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer, 4(1), 128–147. https://doi.org/10.1038/s43018-022-00491-xCrossRefPubMed

71.

So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W. D., et al. (2020). Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic modification and breast cancer colonization. Cancer Research, 80(12), 2612–2627. https://doi.org/10.1158/0008-5472.Can-19-3339CrossRefPubMedPubMedCentral

72.

Fukumoto, T., Fatkhutdinov, N., Zundell, J. A., Tcyganov, E. N., Nacarelli, T., Karakashev, S., et al. (2019). HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Research, 79(21), 5482–5489. https://doi.org/10.1158/0008-5472.CAN-19-1302CrossRefPubMedPubMedCentral

73.

Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019). Phenotypic plasticity: Driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 24(1), 65–78. https://doi.org/10.1016/j.stem.2018.11.011CrossRefPubMed

74.

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3(75), 75ra26. https://doi.org/10.1126/scitranslmed.3002003CrossRefPubMedPubMedCentral

75.

Jang, M. H., Kim, H. J., Kim, E. J., Chung, Y. R., & Park, S. Y. (2015). Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Human Pathology, 46(9), 1267–1274. https://doi.org/10.1016/j.humpath.2015.05.010CrossRefPubMed

76.

Cheung, S. Y., Boey, Y. J., Koh, V. C., Thike, A. A., Lim, J. C., Iqbal, J., et al. (2015). Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Research and Treatment, 152(3), 489–498. https://doi.org/10.1007/s10549-015-3485-1CrossRefPubMed

77.

Rasheed, Z. A., Yang, J., Wang, Q., Kowalski, J., Freed, I., Murter, C., et al. (2010). Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. Journal of the National Cancer Institute, 102(5), 340–351. https://doi.org/10.1093/jnci/djp535CrossRefPubMedPubMedCentral

78.

Wu, S. Z., Al-Eryani, G., Roden, D. L., Junankar, S., Harvey, K., Andersson, A., et al. (2021). A single-cell and spatially resolved atlas of human breast cancers. Nature Genetics, 53(9), 1334–1347. https://doi.org/10.1038/s41588-021-00911-1CrossRefPubMedPubMedCentral

79.

Grasset, E. M., Dunworth, M., Sharma, G., Loth, M., Tandurella, J., Cimino-Mathews, A., et al. (2022). Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. Science Translational Medicine, 14(656), eabn7571. https://doi.org/10.1126/scitranslmed.abn7571CrossRefPubMedPubMedCentral

80.

Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., et al. (2020). Guidelines and definitions for research on epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 21(6), 341–352. https://doi.org/10.1038/s41580-020-0237-9CrossRefPubMedPubMedCentral

81.

Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017). Epithelial-to-mesenchymal transition: Epigenetic reprogramming driving cellular plasticity. Trends in Genetics, 33(12), 943–959. https://doi.org/10.1016/j.tig.2017.08.004CrossRefPubMed

82.

Yuan, S., Natesan, R., Sanchez-Rivera, F. J., Li, J., Bhanu, N. V., Yamazoe, T., et al. (2020). Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. Cancer Discovery, 10(6), 854–871. https://doi.org/10.1158/2159-8290.Cd-19-1299CrossRefPubMedPubMedCentral

83.

Zhang, Y., Donaher, J. L., Das, S., Li, X., Reinhardt, F., Krall, J. A., et al. (2022). Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nature Cell Biology, 24(4), 554–564. https://doi.org/10.1038/s41556-022-00877-0CrossRefPubMedPubMedCentral

84.

Lee, J. E., Wang, C., Xu, S., Cho, Y. W., Wang, L., Feng, X., et al. (2013). H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife, 2, e01503. https://doi.org/10.7554/eLife.01503CrossRefPubMedPubMedCentral

85.

Chen, H., Tu, S. W., & Hsieh, J. T. (2005). Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. The Journal of Biological Chemistry, 280(23), 22437–22444. https://doi.org/10.1074/jbc.m501379200CrossRefPubMed

86.

Xie, D., Gore, C., Liu, J., Pong, R. C., Mason, R., Hao, G., et al. (2010). Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 107(6), 2485–2490.CrossRefPubMedPubMedCentral

87.

Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., De Raedt, T., et al. (2010). An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature Medicine, 16(3), 286–294.CrossRefPubMedPubMedCentral

88.

Cui, J., Zhang, C., Lee, J. E., Bartholdy, B. A., Yang, D., Liu, Y., et al. (2023). MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. Nature Cell Biology. https://doi.org/10.1038/s41556-022-01045-0

89.

Balanis, N. G., Sheu, K. M., Esedebe, F. N., Patel, S. J., Smith, B. A., Park, J. W., et al. (2019). Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies. Cancer Cell, 36(1), 17–34.e17. https://doi.org/10.1016/j.ccell.2019.06.005CrossRefPubMedPubMedCentral

90.

Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., et al. (2021). Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discovery, 11(12), 3028–3047. https://doi.org/10.1158/2159-8290.Cd-20-1863CrossRefPubMedPubMedCentral

91.

Beltran, H., Romanel, A., Conteduca, V., Casiraghi, N., Sigouros, M., Franceschini, G. M., et al. (2020). Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of Clinical Investigation, 130(4), 1653–1668. https://doi.org/10.1172/jci131041CrossRefPubMedPubMedCentral

92.

Chemi, F., Pearce, S. P., Clipson, A., Hill, S. M., Conway, A. M., Richardson, S. A., et al. (2022). cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer, 3(10), 1260–1270. https://doi.org/10.1038/s43018-022-00415-9CrossRefPubMedPubMedCentral

93.

Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., et al. (2016). Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 22(3), 298–305. https://doi.org/10.1038/nm.4045CrossRefPubMedPubMedCentral

94.

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419(6907), 624–629. https://doi.org/10.1038/nature01075CrossRefPubMed

95.

Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., et al. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 355(6320), 78–83. https://doi.org/10.1126/science.aah4199CrossRefPubMedPubMedCentral

96.

Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., et al. (2016). N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell, 30(4), 563–577. https://doi.org/10.1016/j.ccell.2016.09.005CrossRefPubMedPubMedCentral

97.

Xin, L. (2021). EZH2 accompanies prostate cancer progression. Nature Cell Biology, 23(9), 934–936. https://doi.org/10.1038/s41556-021-00744-4CrossRefPubMed

98.

Jung, E., Alfonso, J., Monyer, H., Wick, W., & Winkler, F. (2020). Neuronal signatures in cancer. International Journal of Cancer, 147(12), 3281–3291. https://doi.org/10.1002/ijc.33138CrossRefPubMed

99.

Wingrove, E., Liu, Z. Z., Patel, K. D., Arnal-Estapé, A., Cai, W. L., Melnick, M. A., et al. (2019). Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis. Cell Reports, 27(4), 1277–1292.e1277. https://doi.org/10.1016/j.celrep.2019.03.085CrossRefPubMed

100.

Peluffo, G., Subedee, A., Harper, N. W., Kingston, N., Jovanović, B., Flores, F., et al. (2019). EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis. Cancer Research, 79(16), 4173–4183. https://doi.org/10.1158/0008-5472.Can-18-3264CrossRefPubMedPubMedCentral

101.

Denny, S. K., Yang, D., Chuang, C. H., Brady, J. J., Lim, J. S., Grüner, B. M., et al. (2016). Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell, 166(2), 328–342. https://doi.org/10.1016/j.cell.2016.05.052CrossRefPubMedPubMedCentral

102.

Langille, E., Al-Zahrani, K. N., Ma, Z., Liang, M., Uuskula-Reimand, L., Espin, R., et al. (2022). Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis, and promotes breast cancer. Cancer Discovery, 12(12), 2930–2953. https://doi.org/10.1158/2159-8290.Cd-21-0865CrossRefPubMedPubMedCentral

103.

Al Bakir, M., Huebner, A., Martínez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., et al. (2023). The evolution of non-small cell lung cancer metastases in TRACERx. Nature. https://doi.org/10.1038/s41586-023-05729-x

104.

Pierce, S. E., Granja, J. M., Corces, M. R., Brady, J. J., Tsai, M. K., Pierce, A. B., et al. (2021). LKB1 inactivation modulates chromatin accessibility to drive metastatic progression. Nature Cell Biology, 23(8), 915-924. https://doi.org/10.1038/s41556-021-00728-4.

105.

Vanharanta, S., Shu, W., Brenet, F., Hakimi, A. A., Heguy, A., Viale, A., et al. (2013). Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine, 19(1), 50–56. https://doi.org/10.1038/nm.3029CrossRefPubMed

106.

Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., et al. (2011). Increased methylation variation in epigenetic domains across cancer types. Nature Genetics, 43(8), 768–775. https://doi.org/10.1038/ng.865CrossRefPubMedPubMedCentral

107.

Chen, S., Petricca, J., Ye, W., Guan, J., Zeng, Y., Cheng, N., et al. (2022). The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nature Communications, 13(1), 6467. https://doi.org/10.1038/s41467-022-34012-2CrossRefPubMedPubMedCentral

108.

Li, W., Guo, L., Tang, W., Ma, Y., Wang, X., Shao, Y., et al. (2021). Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer. Clinical Epigenetics, 13(1), 126. https://doi.org/10.1186/s13148-021-01108-3CrossRefPubMedPubMedCentral

109.

Corces, M. R., Granja, J. M., Shams, S., Louie, B. H., Seoane, J. A., Zhou, W., et al. (2018). The chromatin accessibility landscape of primary human cancers. Science, 362(6413). https://doi.org/10.1126/science.aav1898

110.

Cai, W. L., Greer, C. B., Chen, J. F., Arnal-Estapé, A., Cao, J., Yan, Q., et al. (2020). Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain. BMC Medical Genomics, 13(1), 33. https://doi.org/10.1186/s12920-020-0695-0CrossRefPubMedPubMedCentral

111.

Lee, J. H., & Massagué, J. (2022). TGF-β in developmental and fibrogenic EMTs. Seminars in Cancer Biology, 86(Pt 2), 136–145. https://doi.org/10.1016/j.semcancer.2022.09.004CrossRefPubMedPubMedCentral

112.

McDonald, O. G., Wu, H., Timp, W., Doi, A., & Feinberg, A. P. (2011). Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nature Structural & Molecular Biology, 18(8), 867–874. https://doi.org/10.1038/nsmb.2084CrossRef

113.

Song, Y., Zhang, H., Yang, X., Shi, Y., & Yu, B. (2022). Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. European Journal of Medicinal Chemistry, 228, 114042. https://doi.org/10.1016/j.ejmech.2021.114042CrossRefPubMed

114.

Priedigkeit, N., Watters, R. J., Lucas, P. C., Basudan, A., Bhargava, R., Horne, W., et al. (2017). Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI. Insight, 2(17). https://doi.org/10.1172/jci.insight.95703

115.

Bado, I. L., Zhang, W., Hu, J., Xu, Z., Wang, H., Sarkar, P., et al. (2021). The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Developmental Cell, 56(8), 1100–1117.e1109. https://doi.org/10.1016/j.devcel.2021.03.008CrossRefPubMedPubMedCentral

116.

Zhang, W., Bado, I. L., Hu, J., Wan, Y. W., Wu, L., Wang, H., et al. (2021). The bone microenvironment invigorates metastatic seeds for further dissemination. Cell, 184(9), 2471–2486.e2420. https://doi.org/10.1016/j.cell.2021.03.011CrossRefPubMedPubMedCentral

117.

Cote, R. J., Rosen, P. P., Lesser, M. L., Old, L. J., & Osborne, M. P. (1991). Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. Journal of Clinical Oncology, 9(10), 1749–1756. https://doi.org/10.1200/jco.1991.9.10.1749CrossRefPubMed

118.

Cox, T. R. (2021). The matrix in cancer. Nature Reviews. Cancer, 21(4), 217–238. https://doi.org/10.1038/s41568-020-00329-7CrossRefPubMed

119.

Nemec, S., & Kilian, K. A. (2021). Materials control of the epigenetics underlying cell plasticity. Nature Reviews Materials, 6(1), 69–83. https://doi.org/10.1038/s41578-020-00238-zCrossRef

120.

Lamar, J. M., Stern, P., Liu, H., Schindler, J. W., Jiang, Z. G., & Hynes, R. O. (2012). The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proceedings of the National Academy of Sciences of the United States of America, 109(37), E2441–E2450. https://doi.org/10.1073/pnas.1212021109CrossRefPubMedPubMedCentral

121.

Chang, L., Azzolin, L., Di Biagio, D., Zanconato, F., Battilana, G., Lucon Xiccato, R., et al. (2018). The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature, 563(7730), 265–269. https://doi.org/10.1038/s41586-018-0658-1CrossRefPubMedPubMedCentral

122.

Wu, B. K., Mei, S. C., Chen, E. H., Zheng, Y., & Pan, D. (2022). YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. Nature Genetics, 54(8), 1202–1213. https://doi.org/10.1038/s41588-022-01119-7CrossRefPubMedPubMedCentral

123.

Jang, M., An, J., Oh, S. W., Lim, J. Y., Kim, J., Choi, J. K., et al. (2021). Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer. Nature Biomedical Engineering, 5(1), 114–123. https://doi.org/10.1038/s41551-020-00657-xCrossRefPubMed

124.

Elia, I., Doglioni, G., & Fendt, S. M. (2018). Metabolic hallmarks of metastasis formation. Trends in Cell Biology, 28(8), 673–684. https://doi.org/10.1016/j.tcb.2018.04.002CrossRefPubMed

125.

Berger, S. L., & Sassone-Corsi, P. (2016). Metabolic signaling to chromatin. Cold Spring Harbor Perspectives in Biology, 8(11). https://doi.org/10.1101/cshperspect.a019463

126.

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 19(1), 17–30. https://doi.org/10.1016/j.ccr.2010.12.014CrossRefPubMedPubMedCentral

127.

Losman, J. A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., et al. (2013). (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science, 339(6127), 1621–1625. https://doi.org/10.1126/science.1231677CrossRefPubMed

128.

McDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., et al. (2017). Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nature Genetics, 49(3), 367–376. https://doi.org/10.1038/ng.3753CrossRefPubMedPubMedCentral

129.

Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., et al. (2012). Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clinical Cancer Research, 18(22), 6339–6347. https://doi.org/10.1158/1078-0432.Ccr-12-1215CrossRefPubMedPubMedCentral

130.

Yin, M., Guo, Y., Hu, R., Cai, W. L., Li, Y., Pei, S., et al. (2020). Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nature Communications, 11(1), 1833. https://doi.org/10.1038/s41467-020-15290-0CrossRefPubMedPubMedCentral

131.

Wu, L., Cao, J., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., et al. (2018). KDM5 histone demethylases repress immune response via suppression of STING. PLoS Biology, 16(8), e2006134. https://doi.org/10.1371/journal.pbio.2006134CrossRefPubMedPubMedCentral

132.

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., et al. (2018). Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell. Chemistry & Biology, 25(1), 78-87 e75. https://doi.org/10.1016/j.chembiol.2017.09.010CrossRef

133.

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001). Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 98(15), 8554–8559. https://doi.org/10.1073/pnas.141230798CrossRefPubMedPubMedCentral

134.

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., et al. (2014). The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science, 343(6168), 305–309. https://doi.org/10.1126/science.1244917CrossRefPubMed

135.

Kronke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., et al. (2014). Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 343(6168), 301–305. https://doi.org/10.1126/science.1244851CrossRefPubMed

136.

Oser, M. G., Sabet, A. H., Gao, W., Chakraborty, A. A., Schinzel, A. C., Jennings, R. B., et al. (2019). The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes & Development, 33(23-24), 1718–1738. https://doi.org/10.1101/gad.328336.119CrossRef

137.

Teng, Y. C., Lee, C. F., Li, Y. S., Chen, Y. R., Hsiao, P. W., Chan, M. Y., et al. (2013). Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Research, 73(15), 4711–4721. https://doi.org/10.1158/0008-5472.Can-12-3165CrossRefPubMed

138.

Cao, J., Liu, Z., Cheung, W. K., Zhao, M., Chen, S. Y., Chan, S. W., et al. (2014). Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Reports, 6(5), 868–877. https://doi.org/10.1016/j.celrep.2014.02.004CrossRefPubMed

139.

Yu, X., Li, D., Kottur, J., Shen, Y., Kim, H. S., Park, K. S., et al. (2021). A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science Translational Medicine, 13(613), eabj1578. https://doi.org/10.1126/scitranslmed.abj1578CrossRefPubMedPubMedCentral

140.

Nicosia, L., Boffo, F. L., Ceccacci, E., Conforti, F., Pallavicini, I., Bedin, F., et al. (2022). Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene, 41(6), 878–894. https://doi.org/10.1038/s41388-021-02123-7CrossRefPubMed

141.

Maiques-Diaz, A., Spencer, G. J., Lynch, J. T., Ciceri, F., Williams, E. L., Amaral, F. M. R., et al. (2018). Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Reports, 22(13), 3641–3659. https://doi.org/10.1016/j.celrep.2018.03.012CrossRefPubMed

142.

Sheng, W., Liu, Y., Chakraborty, D., Debo, B., & Shi, Y. (2021). Simultaneous inhibition of LSD1 and TGFbeta enables eradication of poorly immunogenic tumors with anti-PD-1 treatment. Cancer Discovery, 11(8), 1970–1981. https://doi.org/10.1158/2159-8290.CD-20-0017CrossRefPubMedPubMedCentral

143.

Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 21(3), 231–238. https://doi.org/10.1038/nm.3799CrossRefPubMed

144.

Rehman, H., Chandrashekar, D. S., Balabhadrapatruni, C., Nepal, S., Balasubramanya, S. A. H., Shelton, A. K., et al. (2022). ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI. Insight, 7(16). https://doi.org/10.1172/jci.insight.155899

145.

Herberts, C., Annala, M., Sipola, J., Ng, S. W. S., Chen, X. E., Nurminen, A., et al. (2022). Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature, 608(7921), 199–208. https://doi.org/10.1038/s41586-022-04975-9CrossRefPubMed

146.

Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J. S., Muhar, M., et al. (2015). Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature, 525(7570), 543–547. https://doi.org/10.1038/nature14898CrossRefPubMedPubMedCentral

147.

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., et al. (2016). Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 529(7586), 413–417. https://doi.org/10.1038/nature16508CrossRefPubMedPubMedCentral

148.

Fong, C. Y., Gilan, O., Lam, E. Y., Rubin, A. F., Ftouni, S., Tyler, D., et al. (2015). BET inhibitor resistance emerges from leukaemia stem cells. Nature, 525(7570), 538–542. https://doi.org/10.1038/nature14888CrossRefPubMedPubMedCentral

149.

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69–80.CrossRefPubMedPubMedCentral

150.

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell, 23(6), 811–825. https://doi.org/10.1016/j.ccr.2013.05.003CrossRefPubMed

151.

Johansson, C., Velupillai, S., Tumber, A., Szykowska, A., Hookway, E. S., Nowak, R. P., et al. (2016). Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nature Chemical Biology, 12(7), 539–545. https://doi.org/10.1038/nchembio.2087CrossRefPubMed

152.

Liu, X., Zhang, S. M., McGeary, M. K., Krykbaeva, I., Lai, L., Jansen, D. J., et al. (2019). KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations. Molecular Cancer Therapeutics, 18(3), 706–717. https://doi.org/10.1158/1535-7163.mct-18-0395CrossRefPubMed

153.

Gale, M., Sayegh, J., Cao, J., Norcia, M., Gareiss, P., Hoyer, D., et al. (2016). Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget, 7(26), 39931-39944. https://doi.org/10.18632/oncotarget.9539.

154.

Hinohara, K., Wu, H. J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., et al. (2018). KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.10.014

Titel: Epigenetic markers and therapeutic targets for metastasis
verfasst von: Carolyn J. Kravitz
Qin Yan
Don X. Nguyen
Publikationsdatum: 07.06.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10109-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Epigenetic markers and therapeutic targets for metastasis

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment

Kenneth V. Honn, Ph.D. (1946–2023)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?

Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead

The role of histone H3 lysine demethylases in glioblastoma

Pancreatic cancer epigenetics: adaptive metabolism reprograms starving primary tumors for widespread metastatic outgrowth

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie